0001209191-18-005228.txt : 20180124
0001209191-18-005228.hdr.sgml : 20180124
20180124184637
ACCESSION NUMBER: 0001209191-18-005228
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180122
FILED AS OF DATE: 20180124
DATE AS OF CHANGE: 20180124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Azelby Robert
CENTRAL INDEX KEY: 0001656998
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36781
FILM NUMBER: 18546321
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVE. NORTH, STE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Juno Therapeutics, Inc.
CENTRAL INDEX KEY: 0001594864
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463656275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 2065821600
MAIL ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-22
0
0001594864
Juno Therapeutics, Inc.
JUNO
0001656998
Azelby Robert
C/O 400 DEXTER AVENUE NORTH
SUITE 1200
SEATTLE
WA
98109
0
1
0
0
EVP & Chief Commercial Officer
Common Stock
2018-01-22
4
M
0
102539
51.76
A
173371
D
Common Stock
2018-01-22
4
S
0
102539
86.25
D
70832
D
Stock Option (Right to Buy)
51.76
2018-01-22
4
M
0
102539
0.00
D
2025-10-31
Common Stock
102539
97461
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
25% of the shares subject to the option vested and became exercisable on November 1, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
/s/ Zachary D. Hale, attorney-in-fact
2018-01-24